Background:Recent artificial tear preparations have provided 0.2%concentration of sodium hyaluronate.However,no published data exist on their potential superiority against 0.1%in alleviating dry-eye-disease symptoms i...Background:Recent artificial tear preparations have provided 0.2%concentration of sodium hyaluronate.However,no published data exist on their potential superiority against 0.1%in alleviating dry-eye-disease symptoms in cataract extraction surgery.Methods:A total of 180 patients that underwent cataract extraction surgery were randomly divided into 2 groups according to their postoperative regime:Study group(SG)received fixed combination of tobramycin and dexamethasone(FCTD)quid for 3 weeks,and additionally 0.2%sodium hyaluronate provided in the COMOD®device quid for 6 weeks.Control group(CG)received fixed combination of tobramycin and dexamethasone(FCTD)quid for 3 weeks,and additionally 0.1%sodium hyaluronate provided in the COMOD®device quid for 6 weeks.The following indexes were evaluated at 3 postoperative checkpoints:(1)Surface discomfort index(SDI)which was derived by four direct 10-scale Likert-type questions that were addressed to the patient and pertained to:(a)foreign body sensation(FBS),(b)blinking discomfort(BD),(c)stinging sensation(SS),(d)tearing sensation(TS),(2)Tear breakup time(TBUT),(3)Schirmer’s test,(4)Central corneal thickness(CCT),and (4)Central Corneal Sensitivity(CCS).Results:Both groups showed reduced CCS values at all postoperative examination points;however,SG participants had significantly better CCS(all p<0.05).SG had better TBUT than CG at the 3rd(p=0.03)and 6th examination points(p=0.04).Moreover,SG had better SDI scores at the 3rd(SDI=9.26±0.55)and 6th weeks(SDI=9.47±0.48)vs.CG participants(p=0.03 and p<0.01,respectively).Conclusion:The increased 0.2%sodium hyaluronate concentration in the artificial tears provided in the COMOD®device seems to address dry-eye-disease symptoms better in patients who underwent phacoemulsification surgery than the 0.1%concentration.Trial registration:ClinicalTrials.gov Identifier:NCT03705949 Oct 15,2018,retrospectively registered.展开更多
文摘Background:Recent artificial tear preparations have provided 0.2%concentration of sodium hyaluronate.However,no published data exist on their potential superiority against 0.1%in alleviating dry-eye-disease symptoms in cataract extraction surgery.Methods:A total of 180 patients that underwent cataract extraction surgery were randomly divided into 2 groups according to their postoperative regime:Study group(SG)received fixed combination of tobramycin and dexamethasone(FCTD)quid for 3 weeks,and additionally 0.2%sodium hyaluronate provided in the COMOD®device quid for 6 weeks.Control group(CG)received fixed combination of tobramycin and dexamethasone(FCTD)quid for 3 weeks,and additionally 0.1%sodium hyaluronate provided in the COMOD®device quid for 6 weeks.The following indexes were evaluated at 3 postoperative checkpoints:(1)Surface discomfort index(SDI)which was derived by four direct 10-scale Likert-type questions that were addressed to the patient and pertained to:(a)foreign body sensation(FBS),(b)blinking discomfort(BD),(c)stinging sensation(SS),(d)tearing sensation(TS),(2)Tear breakup time(TBUT),(3)Schirmer’s test,(4)Central corneal thickness(CCT),and (4)Central Corneal Sensitivity(CCS).Results:Both groups showed reduced CCS values at all postoperative examination points;however,SG participants had significantly better CCS(all p<0.05).SG had better TBUT than CG at the 3rd(p=0.03)and 6th examination points(p=0.04).Moreover,SG had better SDI scores at the 3rd(SDI=9.26±0.55)and 6th weeks(SDI=9.47±0.48)vs.CG participants(p=0.03 and p<0.01,respectively).Conclusion:The increased 0.2%sodium hyaluronate concentration in the artificial tears provided in the COMOD®device seems to address dry-eye-disease symptoms better in patients who underwent phacoemulsification surgery than the 0.1%concentration.Trial registration:ClinicalTrials.gov Identifier:NCT03705949 Oct 15,2018,retrospectively registered.
